🍂 Enjoy the Fall Season! 🍂
MindTheDesk

Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

News Archived • November 10, 2026 •
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatmentThe gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine Foundation has warned.GLP-1 blockbuster medications such as Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro have revolutionised obesity and diabetes treatment but there has been a greater focus by companies on weight loss, according to a report from the Netherlands-based non-profit group. Continue reading...
Source: Guardian US | https://www.theguardian.com/us-news/rss - Read Original
"We build AI or anything ICST"
"House Plans for Structures New and Old"

Discussion (0)

Please log in to post a comment.

No comments yet. Be the first to share your thoughts!

Sponsored
"Retirement Health Care"
"Network Cable Repairs from $29"